25/09/2025 - Campus Can Ruti, Research
A group of genes could anticipate the response to a key breast cancer treatment
A study coordinated from Badalona by IrsiCaixa, the Catalan Institute of Oncology and the Germans Trias i Pujol Research Institute (within the CARE programme) has identified KIMA, a genomic signature that makes it possible to anticipate which patients with HR+/HER2- breast cancer will respond less well to CDK4/6 inhibitors. The finding, published in the journal Clinical and Translational Medicine, may help personalize therapies and design new combinations.